Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials

被引：0
|
作者：
Gaede, Peter
Catarig, Andrei-Mircea
Dungan, Kathleen M.
Hindsberger, Charlotte
Ollgaard, Jens
Bain, Stephen C.
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-660-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
660-P
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program
    Pratley, Richard E.
    Aroda, Vanita R.
    Hindsberger, Charlotte
    Kose, Yasemin
    Kaltoft, Margit
    Jodar, Esteban
    DIABETES, 2021, 70
  • [2] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    DIABETES, 2016, 65 : A49 - A49
  • [3] Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme
    Jodar, E.
    Aroda, V. R.
    Kose, Y.
    Kaltoft, M.
    Sondergaard, A. L.
    Pratley, R.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 250 - 250
  • [4] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [5] Greater Proportions of Subjects Achieved HbA1c <7% without Weight Gain, Hypoglycemia, or Moderate/Severe Gastrointestinal Adverse Events with Semaglutide vs. Comparators in the SUSTAIN 7-10 Trials
    Khunti, Kamlesh
    Hindsberger, Charlotte
    Lawson, Jack
    Vrhnjak, Blaz
    Le Roux, Carel
    DIABETES, 2021, 70
  • [6] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [7] Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
    Jendle, Johan
    Birkenfeld, Andreas L.
    Polonsky, William H.
    Silver, Robert
    Uusinarkaus, Kari
    Hansen, Thomas
    Hakan-Bloch, Jonas
    Tadayon, Sayeh
    Davies, Melanie J.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2315 - 2326
  • [8] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    DIABETES, 2021, 70
  • [9] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, Andrew
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Annett, Miriam
    Aroda, Vanita
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [10] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, A.
    Capehom, M.
    Charpentier, G.
    Dotta, E.
    Henkel, E.
    Lingvay, I.
    Holst, A. Gaarsdal
    Annett, M.
    Aroda, V.
    DIABETOLOGIA, 2016, 59 : S76 - S76
12345